美国的甲状腺癌临床试验：了解趋势以实现最大影响。
Thyroid cancer clinical trials in the United States: Understanding trends to maximize impact.
作者信息
Hsieh Alan, Murchison Charles, Devaiah Anand
机构信息
Boston University School of Medicine, Boston, Massachusetts.
Department of Emergency Medicine, State University of New York Downstate-Kings County Hospital, Brooklyn, New York.
出版信息
Head Neck. 2019 Jul;41(7):2346-2352. doi: 10.1002/hed.25703. Epub 2019 Feb 18.
BACKGROUND
We sought to understand thyroid cancer study modalities, publications, and grants. This provides scope, resources, and dissemination patterns to inform future directions for research and policy.
METHODS
A retrospective study of thyroid cancer trials using ClinicalTrials.gov was performed. Publication and grant awards were sourced using PubMed.gov and NIH RePORTER, respectively.
RESULTS
Seventy-three thyroid cancer trials were identified out of 217 000 from 1998 to 2015. Drugs were studied in 96% of all trials. Only 14% of all trials included radiation, and 4% included surgery. Only 29% of trials published their results, NIH funding was reported for 26% of trials. Total funding was $1 845 567 484 (average award: $97135131).
CONCLUSION
This study is the first to prove that drug trials predominate in thyroid cancer and quantify NIH dollars awarded. Radiation and surgery are underrepresented, despite being standard of care. We recommend better balance of therapeutics and peer-reviewed reporting of positive and negative results.
LEVEL OF EVIDENCE
Level 1a evidence.
背景
我们试图了解甲状腺癌的研究模式、出版物及资助情况。这为未来研究及政策方向提供了范围、资源及传播模式。
方法
对使用ClinicalTrials.gov的甲状腺癌试验进行回顾性研究。出版物及资助奖项分别通过PubMed.gov和美国国立卫生研究院报告系统（NIH RePORTER）获取。
结果
在1998年至2015年的217000项试验中，确定了73项甲状腺癌试验。所有试验中有96%研究了药物。所有试验中仅14%包括放射治疗，4%包括手术。仅29%的试验公布了结果，26%的试验报告获得了美国国立卫生研究院的资助。总资助金额为1845567484美元（平均资助额：97135131美元）。
结论
本研究首次证明甲状腺癌试验以药物试验为主，并对美国国立卫生研究院授予的资金进行了量化。尽管放射治疗和手术是标准治疗方法，但在研究中所占比例较低。我们建议在治疗方法上实现更好的平衡，并对阳性和阴性结果进行同行评审报告。
证据级别
1a级证据。
Zotero 插件